TABLE 8.

Summary of reviewed studies dealing with Versa TREK systema

DrugAuthors (reference)YrCC (μg/ml)No. of:Sens.Spec.PPVNPVDOR
Tested strainsTPFNFPTN
SMBergmann and Woods (8)19988.020180111.000.500.951.003.61
Ruiz et al. (31)20008.038937700121.001.001.001.009.85
INHBergmann and Woods (8)19980.120160221.000.500.891.003.50
0.420180111.000.500.951.003.61
Ruiz et al. (31)20000.13892014401440.821.001.000.777.18
0.4389241021461.000.990.991.0010.25
RMPBergmann and Woods (8)19981.020170031.001.001.001.005.50
Ruiz et al. (31)20001.038934500441.001.001.001.0011.03
EMBBergmann and Woods (8)19988.020200001.00NA1.00NA3.71
Ruiz et al. (31)20008.03893870021.001.001.001.008.26
PZALaBombardi (19)200230050420081.001.001.001.007.28
  • a Data are reported by individual drug. DORs are expressed as logarithms. TP, true positive; FN, false negative; FP, false positive; TN, true negative; Sens., sensitivity; Spec., specificity; PPV, positive predictive value; NPV, negative predictive value; NA, not available.